African Philanthropists Must Drive Change in Public Health
Understand how African philanthropists can lead the way in health improvement efforts, saving lives and supporting innovation.
Generic HIV Prevention Drug to Cost Just $40 Annually from 2027
Explore the benefits of the generic HIV prevention drug lenacapavir, set to change the landscape of global health by 2027.
HIV Prevention Injection Changes the Game in Treatment
Discover the new HIV prevention injection coming to South Africa. Learn how lenacapavir offers a game-changing alternative to daily pills.
HIV Prevention Injection Changes the Game in Treatment
Discover the new HIV prevention injection coming to South Africa. Learn how lenacapavir offers a game-changing alternative to daily pills.
Sakeliga’s NHI Legal Battle for Constiutional Justice
Learn about Sakeliga's NHI legal battle as they challenge the constitutionality of South Africa's National Health Insurance plan.
Lenacapavir for HIV Prevention in South Africa
South Africa will introduce lenacapavir for HIV prevention in 2026, offering a new hope in the fight against HIV.
UNAIDS and the Fight Against Global AIDS Progress
The UNAIDS Global Aids Update 2025 highlights urgent challenges in HIV response due to funding cuts threatening progress.
HIV/AIDS Funding Gap: Government Steps In
The South African government has stepped in with a crucial R753.5 million injection from the National Treasury to sustain the nation’s HIV/Aids programmes. This vital funding seeks to close the HIV/AIDS funding gap. The withdrawal of the United States President’s Emergency Plan for AIDS Relief (PEPFAR) significantly impacted this gap. This move had threatened to…...
Twice-Yearly HIV Jab: Activists Call for Lower Prices
Explore the revolutionary Twice-Yearly HIV Jab, a potential game-changer in HIV prevention that raises important affordability questions.
Global fund affirms commitment to lenacapavir rollout
The Global Fund for HIV, TB, and Malaria reaffirms its commitment to introducing the twice-yearly HIV prevention jab, lenacapavir, in underprivileged countries.